A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMISE 1
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 27 Jun 2017 According to an Alder Biopharmaceuticals media release, based on the data from PROMISE 1, PROMISE 2 studies the company expects to file a Biologics License Application (BLA) to the FDA for eptinezumab in the second half of 2018.
    • 27 Jun 2017 Primary endpoint has been met. (Change in frequency of migraine days), as reported in an Alder Biopharmaceuticals media release.
    • 27 Jun 2017 Top-line results published in Alder Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top